source
- Odyssey Therapeutics raises $279 million in IPO, adds $25 million private saleOdyssey Therapeutics, a biotech focused on autoimmune diseases, completed an initial public offering that generated $279 million by selling 15.5 million shares at $18 each. The company also secured…
- Pimicotinib shows 76% response rate and functional benefits in TGCT phase 3 trialDr. Randall discussed results from the phase 3 MANEUVER trial of the CSF-1 receptor inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data were presented at the 2025…